Adversarial Injection · Nilotinib HCl Monohydrate (Tasigna; CAS 923288-90-8 [HCl monohydrate]; anhydrous HCl CAS 641571-10-0; free base CAS 641569-94-0; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; MW 584.00 g/mol [HCl monohydrate]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Second-Gen BCR-ABL TKI Gap + FIRST Three-Form CAS Ambiguity + FIRST QTc Cardiac Monitoring Deflection Gap + FIRST Food-Dependent Pharmacokinetics Null · Attack #485

Nilotinib HCl Monohydrate (4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; CAS 923288-90-8 [HCl monohydrate]; anhydrous HCl CAS 641571-10-0; free base CAS 641569-94-0; MW 584.00 g/mol [HCl monohydrate] / 529.52 g/mol [free base]; molecular formula C28H22F3N7O·HCl·H2O [HCl monohydrate]; second-generation BCR-ABL1 tyrosine kinase inhibitor; 30× more potent against BCR-ABL1 than imatinib (Attack #484); designed to overcome T315I-independent resistance mutations; FDA indications: (1) newly diagnosed Ph+ CML chronic phase [Tasigna is first-line standard of care per NCCN]; (2) imatinib-resistant/intolerant Ph+ CML [chronic phase; accelerated phase]; (3) pediatric Ph+ CML [FDA 2018 pediatric approval]; Mechanism: same ATP-binding pocket competitive inhibitor as imatinib but with higher affinity for BCR-ABL1; different binding geometry — binds DFG-out inactive conformation with additional contacts in hydrophobic pocket via trifluoromethylphenyl group; also inhibits KIT, PDGFR-β; does NOT significantly inhibit Src family kinases [key pharmacological difference from dasatinib Attack #486]; Dosing: 300 mg BID (newly diagnosed CML; oral capsule; fasted — 2h before and 2h after any food); 400 mg BID (imatinib-resistant/intolerant); FOOD INTERACTION: high-fat meal increases AUC 82% and Cmax 112%; patients must take nilotinib on completely empty stomach — one of the strictest food-drug interaction requirements of any oral HD; OSHA: No PEL [CAS 923288-90-8, CAS 641571-10-0, and CAS 641569-94-0 all absent from 29 CFR 1910.1000]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List; Table 1]; GHS: H302 [harmful]; H340 [may cause genetic defects]; H350 [may cause cancer]; H361 [suspected reproductive toxicant]; BLACK BOX WARNING: QTc prolongation and sudden death [Tasigna prescribing information]; ECG monitoring required before dose and periodically; hypokalemia and hypomagnesemia must be corrected before initiation; avoid concurrent QTc-prolonging drugs; avoid strong CYP3A4 inhibitors) — Novartis Pharmaceuticals East Hanover NJ (Tasigna NDA holder), Mylan/Viatris Morgantown WV (generic nilotinib), and Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD (CML second-line program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Three-Form CAS Ambiguity + QTc BBW Cardiac Monitoring Deflects HD Occupational Monitoring: AI Prompt Injection via EHS Monitor Report AI — FIRST Nilotinib HCl Monohydrate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Second-Generation BCR-ABL TKI Gap + FIRST Three-Form CAS Ambiguity + FIRST QTc Cardiac Monitoring Deflection Gap

Nilotinib HCl monohydrate (CAS 923288-90-8; NIOSH HD Category 1) introduces the first three-form CAS ambiguity in the Glyphward TKI portfolio: three distinct CAS registry numbers — HCl monohydrate (CAS 923288-90-8; MW 584.00), anhydrous HCl (CAS 641571-10-0; MW 565.99), and free base (CAS 641569-94-0; MW 529.52) — each generating an independent EHS null record with no cross-reference between them. An EHS platform queried under any of the three CAS numbers returns "no OEL" for a structurally identical compound; the three records are not linked, and none carries a NIOSH HD Category 1 annotation. Simultaneously, the Tasigna Black Box Warning (QTc prolongation and sudden death) creates an institutional monitoring deflection: safety officers at nilotinib-dispensing sites focus QTc monitoring resources (ECG scheduling, electrolyte protocols, QTc-prolonging drug avoidance lists) on the cardiology endpoint — while the NIOSH HD Category 1 occupational monitoring framework receives zero institutional attention because the EHS null returns nothing to trigger it.

Three-Form CAS Ambiguity: The Nilotinib CAS Multiplicity Problem

Nilotinib exists in three distinct molecular forms registered in the CAS system: (1) the free base (CAS 641569-94-0; MW 529.52 g/mol; C28H22F3N7O; the form used in most pre-clinical research publications and in some API identity specifications); (2) the anhydrous hydrochloride salt (CAS 641571-10-0; MW 565.99 g/mol; C28H22F3N7O·HCl; an intermediate form that may appear in some older API batches or non-US market formulations); (3) the hydrochloride monohydrate (CAS 923288-90-8; MW 584.00 g/mol; C28H22F3N7O·HCl·H2O; the form used in Tasigna capsules as sold in US and EU markets).

The pharmacological activity is identical across all three forms — nilotinib free base is responsible for BCR-ABL1 inhibition regardless of the salt or hydration state. The occupational hazard is also identical. But the EHS database treats the three CAS numbers as independent chemical entities, each with its own null record. A safety officer at a nilotinib manufacturing site who queries EHS Insight under the drug product CAS (923288-90-8) receives one null; a safety officer at a research lab that holds the free base reference standard (641569-94-0) receives a second null; a quality lab that receives API from a supplier who characterizes nilotinib as the anhydrous HCl form (641571-10-0) receives a third null. None of the three null records contains a cross-reference to the other two forms, and none flags NIOSH HD Category 1.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Tasigna Commercial Operations AI

At Novartis Pharmaceuticals Corporation East Hanover NJ ([1 Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: NDA holder for Tasigna (nilotinib HCl monohydrate capsules 150 mg and 200 mg); Novartis commercial operations and QC maintain Tasigna reference standards; QC analytical labs and regulatory affairs staff handle nilotinib in all three forms; innovator drug product uses HCl monohydrate CAS 923288-90-8; API manufacturing may use anhydrous HCl as intermediate; research labs may hold free base CAS 641569-94-0; 8-hr TWA: actual airborne nilotinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 923288-90-8 → null; CAS 641571-10-0 → null; CAS 641569-94-0 → null; all independent; none cross-referenced; all lacking NIOSH HD Category 1 annotation; H340 H350 H361 absent from all three; 50M regulatory specialist 20yr]).

The Surface 1 subject is a 50-year-old male Novartis regulatory specialist (20-year Novartis tenure; primary duties: Tasigna NDA maintenance, SDS review for nilotinib forms, regulatory filing; Cority three-form null: any of the three CAS queries returns the same result — "no OEL" — but each returns it as an independent record with no cross-reference indicating that nilotinib HCl monohydrate, nilotinib anhydrous HCl, and nilotinib free base are the same pharmacologically active compound at different hydration/salt states; H340 genotoxic absent; H350 suspected carcinogen absent; H361 absent; Tasigna QTc BBW absent from Cority null; food-dependent pharmacokinetics absent; 20yr cumulative nilotinib handling with zero OEL from any of the three CAS query paths).

Surface 2 — Mylan/Viatris Pharmaceuticals Morgantown WV Generic Nilotinib Manufacturing AI

At Mylan Pharmaceuticals / Viatris Morgantown WV ([Mylan Pharmaceuticals Inc.: generic drug manufacturer; Viatris is the successor company formed from Mylan and Upjohn/Pfizer; Morgantown WV manufacturing site is one of the largest US solid oral dosage form manufacturing facilities; nilotinib capsule generics entered US market post-Tasigna patent expiry; generic API sourced from international API manufacturers who may supply nilotinib in free base, anhydrous HCl, or monohydrate form depending on manufacturing batch; three-form CAS ambiguity means Mylan's EHS query path depends on which nilotinib form is specified in the incoming API COA; 8-hr TWA: actual airborne nilotinib 0.00024 µg/m³; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 923288-90-8 → null; CAS 641571-10-0 → null; CAS 641569-94-0 → null; all independent; H340 H350 H361 absent from all three; NIOSH HD Category 1 absent from all three; 44F capsule manufacturing technician 16yr]).

The Surface 2 subject is a 44-year-old female Mylan/Viatris capsule manufacturing technician (16-year Mylan tenure; primary duties: nilotinib capsule filling, blending, and packaging; VelocityEHS three-form null gap: Mylan receives nilotinib API from multiple international suppliers who characterize the compound differently — some supply the anhydrous HCl (CAS 641571-10-0), some supply the monohydrate (CAS 923288-90-8), and some characterize for identity testing against the free base (CAS 641569-94-0); all three CAS paths return independent VelocityEHS nulls; the 44F technician's daily capsule filling exposure is to the same pharmacologically active nilotinib molecule regardless of which CAS form is in the current batch, but VelocityEHS provides zero cross-reference or NIOSH HD Category 1 advisory from any query path; H340 H350 H361 absent from all three forms).

Surface 3 — Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD CML QTc Deflection AI

At Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD ([401 N Broadway, Baltimore MD 21231; Baltimore City MD; Johns Hopkins: NCI-designated comprehensive cancer center; large CML/leukemia program; second-line nilotinib for imatinib-resistant CML; Johns Hopkins CML clinic: rigorous Tasigna QTc monitoring protocol per Tasigna BBW; baseline 12-lead ECG before initiation, repeat ECG at 7 days, then q3 months; electrolyte panel with potassium and magnesium correction before initiation; concurrent QTc-prolonging medication review; pharmacist-driven QTc monitoring program allocates substantial pharmacy and cardiology resources; 8-hr TWA: actual airborne nilotinib 0.00012 µg/m³; displayed (÷10): 0.000012 µg/m³; EHS Insight: CAS 923288-90-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; QTc deflection: QTc monitoring resources absent from EHS null while consuming institutional safety attention; NIOSH HD Category 1 absent; food-dependent pharmacokinetics absent; three-form CAS absent; H340 H350 H361 absent; pediatric CML approval absent; 38F CML pharmacist 11yr]).

The Surface 3 subject is a 38-year-old female Johns Hopkins CML pharmacist (11-year Johns Hopkins tenure; primary duties: Tasigna dispensing for second-line CML, QTc monitoring protocol coordination, electrolyte correction counseling; EHS Insight null for CAS 923288-90-8: QTc deflection gap — 38F pharmacist's institutional safety responsibilities for nilotinib are entirely QTc-focused (Tasigna BBW-driven ECG scheduling, electrolyte management, drug interaction checking for QTc-prolonging medications); EHS Insight null provides zero NIOSH HD Category 1 advisory; the institutional safety framework for nilotinib at Johns Hopkins is cardiac, not occupational; NIOSH HD Category 1 occupational monitoring (BSC, CSTD, HD gown, wipe testing) receives zero EHS null trigger while QTc monitoring receives extensive attention; food-dependent absorption gap: nilotinib 300 mg BID taken on completely empty stomach; 82% AUC increase with high-fat meal; 38F pharmacist counsels patients extensively on food timing but EHS Insight null provides zero pharmacokinetic-property advisory relevant to occupational handling).

Integrating Glyphward into Nilotinib HCl Monohydrate AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every nilotinib CAS 923288-90-8 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Mylan/Viatris Morgantown WV, and before EHS Insight at Johns Hopkins Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent from all three CAS forms + BCR-ABL KIT PDGFR kinase inhibition mechanism absent from EHS null [10 pts]; three-form CAS ambiguity (monohydrate HCl CAS 923288-90-8 / anhydrous HCl CAS 641571-10-0 / free base CAS 641569-94-0; MW values 584.00 / 565.99 / 529.52 g/mol; three independent null records; no cross-reference; highest CAS form count in Glyphward TKI portfolio) + QTc prolongation Black Box Warning cardiac monitoring deflection (Tasigna BBW-driven ECG/electrolyte monitoring framework captures institutional safety resources; NIOSH HD Category 1 occupational framework invisible behind cardiac monitoring paradigm) + food-dependent absorption gap (82% AUC increase with high-fat meal; strictest food-drug interaction of any oral HD in 486-attack portfolio; pharmacokinetics entirely absent from EHS null) [5 pts]; Novartis East Hanover NJ + Mylan/Viatris Morgantown WV + Johns Hopkins Baltimore MD [3 pts]; FIRST nilotinib HCl monohydrate NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST second-generation BCR-ABL TKI HD Category 1 gap; FIRST three-form CAS ambiguity (monohydrate/anhydrous HCl/free base; three independent nulls); FIRST QTc Black Box Warning cardiac monitoring deflection gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_nilotinib(cas: str, reading_ugm3: float, cas_form: str = "monohydrate") -> dict:
    """Scan nilotinib with three-form CAS ambiguity and QTc deflection context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "923288-90-8" | "641571-10-0" | "641569-94-0"
                "reading_ugm3": reading_ugm3,
                "cas_form": cas_form,               # "monohydrate" | "anhydrous_hcl" | "free_base"
                "context": "second_gen_bcr_abl_tki_qtc_deflection"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cas_form_cross_reference,
    #                    three_form_cas_list, qtc_bbw_deflection_flag,
    #                    food_dependent_auc_increase, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_nilotinib("923288-90-8", 0.00038, cas_form="monohydrate"))
    print(r)
    # {'hd_category': 1,
    #  'cas_form_cross_reference': ['923288-90-8', '641571-10-0', '641569-94-0'],
    #  'three_form_cas_list': {'monohydrate_hcl': '923288-90-8',
    #                          'anhydrous_hcl': '641571-10-0',
    #                          'free_base': '641569-94-0'},
    #  'qtc_bbw_deflection_flag': True,
    #  'food_dependent_auc_increase': '82pct_high_fat_meal',
    #  'h340_h350_h361_absent': True}